Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
November 6, 2017
HTML PDF
New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa)
November 3, 2017
HTML PDF
New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting
November 1, 2017
HTML PDF
Alexion to Present at the 26th Annual Credit Suisse Healthcare Conference
October 30, 2017
HTML PDF
Alexion Reports Third Quarter 2017 Results
October 26, 2017
HTML PDF
FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
October 23, 2017
HTML PDF
Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017
October 10, 2017
HTML PDF
Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors
September 14, 2017
HTML PDF
Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris® (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis
September 13, 2017
HTML PDF
Alexion Announces Restructuring to Advance Corporate Strategy
September 12, 2017
HTML PDF